Quarterly report · Q2
9273.TEDINET S100Q755
Period2022-07-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.2bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.4bn | 2021-07-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥2.2bn | 2021-07-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2021-07-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.1bn | 2021-07-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2021-07-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2021-07-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥27.6bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥26.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥25.7bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥7.6bn | at 2022-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥19.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥18.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥17.7bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.9bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.2bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2021-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥518m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥440m | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥120m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥477m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥264m | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥600m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥805m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥576m | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥35.19 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.9 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.28 | 2021-07-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.98 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 70.8% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.9% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | ¥22m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥8.1bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥761m |
| —segment total | revenue | 2022-07-01 → 2022-12-31 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-12-31 | ¥11.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| —segment total | segment profit | 2022-07-01 → 2022-12-31 | ¥2.1bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-12-31 | −¥964m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-12-31 | −¥964m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-12-31 | ¥19m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥7.4bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥6.5bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥964m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥1.3bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥3.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥3.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥862m |
| —segment total | revenue | 2021-07-01 → 2021-12-31 | ¥11.3bn |
| —segment total | revenue external | 2021-07-01 → 2021-12-31 | ¥10.4bn |
| —segment total | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥964m |
| —segment total | segment profit | 2021-07-01 → 2021-12-31 | ¥2.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -6401000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -3661000 | JPY |
| Proceeds from subsidy ope cf | Prior1YTDDuration | 3523000 | JPY |
| Proceeds from subsidy ope cf | CurrentYTDDuration | 766000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -682901000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -795361000 | JPY |
| Settlement package paid ope cf | Prior1YTDDuration | -16000000 | JPY |
| Settlement package paid ope cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 440090000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 518384000 | JPY |
| Purchase of noncurrent assets inv cf | Prior1YTDDuration | -248372000 | JPY |
| Purchase of noncurrent assets inv cf | CurrentYTDDuration | -104085000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -79011000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -85011000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 66010000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 72011000 | JPY |
| Other net inv cf | Prior1YTDDuration | -2652000 | JPY |
| Other net inv cf | CurrentYTDDuration | -2698000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -264025000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -119784000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -167618000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -150952000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -395294000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -436130000 | JPY |
| Other net fin cf | Prior1YTDDuration | -13105000 | JPY |
| Other net fin cf | CurrentYTDDuration | -12971000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -576018000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -600053000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 13129000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 416000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -386823000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -201037000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 7590119000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 8421859000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 7203295000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 8220822000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 111575000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 109356000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 283387000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 284014000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 11226000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 10163000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 26202000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 25205000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 6476000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 6216000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 6466782000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 3888476000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 10355258000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |